Valaciclovir
- Generic Name
- Valaciclovir
- Brand Names
- Valtrex
- Drug Type
- Small Molecule
- Chemical Formula
- C13H20N6O4
- CAS Number
- 124832-26-4
- Unique Ingredient Identifier
- MZ1IW7Q79D
- Background
Valaciclovir (valacyclovir), also known as Valtrex, is an antiviral drug that has been used to manage and treat various herpes infections for more than 2 decades. It was initially approved by the FDA in 1995 and marketed by GlaxoSmithKline . Valacyclovir is the L-valine ester of aciclovir. It is a member of the purine (guanine) nucleoside analog drug class ...
- Indication
Valacyclovir is a nucleoside analog DNA polymerase inhibitor indicated for :
Adults
• Cold Sores (Herpes Labialis)
• Genital Herpes
• Treatment of genital herpes lesions in immunocompetent patients (initial or recurrent episode)
• Suppression of genital herpes lesions in immunocompetent or HIV-infected patients
• Reduction of viral transmission
...
- Associated Conditions
- Chickenpox, Genital Herpes, Genital herpes, initial episode, Herpes Labialis, Herpes Zoster, Recurrent Genital Herpes (RGH)
- Associated Therapies
- Suppression of Recurrent Genital Herpes (RGH)
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT05536349
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study Exploring Efficacy of Peginterferon in Patients With Herpes Zoster
- Conditions
- Interventions
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Shanghai Institute Of Biological Products
- Target Recruit Count
- 50
- Registration Number
- NCT05492591
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Dermatology Hospital, Nanjing, Jiangsu, China
Neonatal Phase 1 Valacyclovir Study
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 16
- Registration Number
- NCT05468619
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases, Louisville, Kentucky, United States
🇺🇸Steven and Alexandra Cohen Childrens Medical Center of New York - New Hyde Park - Infectious Disease, Queens, New York, United States
Using Oral Valacyclovir to Treat Patients With Refractory IC/BPS
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- Buddhist Tzu Chi General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05094414
- Locations
- 🇨🇳
Hualien Tzu Chi Hospital, Hualien City, Taiwan
Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel
- Conditions
- Interventions
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2020-12-11
- Lead Sponsor
- Nearmedic Plus LLC
- Target Recruit Count
- 45
- Registration Number
- NCT04664127
- Locations
- 🇷🇺
Scientific Information Center for Prevention and Treatment of Viral Infections, Moscow, Russian Federation
Valacyclovir in Neonatal Herpes Simplex Virus Disease
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 10
- Registration Number
- NCT04448392
- Locations
- 🇺🇸
University of Alabama - Children's of Alabama, Birmingham, Alabama, United States
Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection
- Conditions
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Heidelberg ImmunoTherapeutics GmbH
- Target Recruit Count
- 122
- Registration Number
- NCT04165122
- Locations
- 🇩🇪
emovis GmbH, Berlin, Germany
🇩🇪WIR "Walk In Ruhr" im St. Elisabeth Hospital, Bochum, Germany
🇩🇪Praxis Jessen2+Kollegen, Berlin, Germany
Pharmacokinetics of Valacyclovir Oral Solution in Children
- Conditions
- Interventions
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 7
- Registration Number
- NCT04081480
- Locations
- 🇳🇱
Prinses Maxima Centrum voor kinderoncologie, Utrecht, Netherlands
Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control Trial
- Conditions
- Interventions
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Belfast Health and Social Care Trust
- Target Recruit Count
- 85
- Registration Number
- NCT03699904
- Locations
- 🇬🇧
Belfast Health and Social Care Trust, Belfast, Down, United Kingdom
GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas
- Conditions
- Interventions
- First Posted Date
- 2018-07-03
- Last Posted Date
- 2023-06-29
- Target Recruit Count
- 36
- Registration Number
- NCT03576612
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.